戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 e double-combination regimen (zidovudine and didanosine).
2  or combination therapy with zidovudine plus didanosine.
3 e zidovudine, didanosine, or zidovudine plus didanosine.
4 ovudine plus zalcitabine, or zidovudine plus didanosine.
5 he risk of NCPH in HIV patients treated with didanosine.
6 ne plus 2.25 mg of zalcitabine; or 400 mg of didanosine.
7 amivudine and abacavir, but not stavudine or didanosine.
8 ide drugs such as zidovudine, stavudine, and didanosine.
9         All patients received zidovudine and didanosine; 100 received nevirapine and 98 received plac
10 alone (32 percent) than with zidovudine plus didanosine (18 percent; relative hazard ratio, 0.50; P<0
11  and 2) open-label zidovudine (600 mg/d) and didanosine (400 mg/d for patients weighing > or = 60 kg)
12  stavudine/lamivudine (17.6%), and stavudine/didanosine (5.4%).
13 ovudine; 600 mg of zidovudine plus 400 mg of didanosine; 600 mg of zidovudine plus 2.25 mg of zalcita
14 the 363 patients assigned to zidovudine plus didanosine, 63 percent of the 367 assigned to zidovudine
15 t; relative hazard ratio, 0.54; P<0.001), or didanosine alone (22 percent; relative hazard ratio, 0.6
16 r neutropenia was seen in patients receiving didanosine alone (P=0.036).
17                     At the end of the study, didanosine alone had an efficacy similar to that of zido
18 ith zidovudine alone as compared with either didanosine alone or combination therapy with zidovudine
19 HIV-infected children, treatment with either didanosine alone or zidovudine plus didanosine was more
20  didanosine, zidovudine plus zalcitabine, or didanosine alone slows the progression of HIV disease an
21                              The efficacy of didanosine alone was similar to that of the combination
22 eated with zidovudine alone, 0.65+/-0.07 for didanosine alone, 0.93+/-0.10 for zidovudine plus didano
23 ndomly assigned to receive zidovudine alone, didanosine alone, zidovudine plus didanosine, or zidovud
24 ine plus zalcitabine, and 0.69 (P=0.019) for didanosine alone.
25 An association between use of zidovudine and didanosine and a rare but life-threatening syndrome of h
26 lacebo once daily) (n = 285) plus open-label didanosine and efavirenz, once daily.
27 ce-daily stavudine when used with once-daily didanosine and efavirenz.
28                                              Didanosine and hydroxyurea were added to the antiretrovi
29               Thus, combination therapy with didanosine and IFN-alpha can be safely administered to p
30 as undertaken to evaluate the combination of didanosine and interferon-alpha (INF-alpha) in human imm
31 cond regimen, as compared with starting with didanosine and stavudine (hazard ratio, 0.68), and signi
32 vudine and lamivudine or a regimen including didanosine and stavudine in combination with either nelf
33 nz and nelfinavir in combination with either didanosine and stavudine or zidovudine and lamivudine wi
34  lamivudine (but not efavirenz combined with didanosine and stavudine) appeared to delay the failure
35 d to make them more convenient (specifically didanosine and stavudine).
36 osine alone, 0.93+/-0.10 for zidovudine plus didanosine, and 0.89+/-0.06 for zidovudine plus zalcitab
37 uple-drug therapy with adefovir, lamivudine, didanosine, and efavirenz provides pronounced and durabl
38 eatment with adefovir dipivoxil, lamivudine, didanosine, and efavirenz.
39          Severe immunodeficiency, stavudine, didanosine, and indinavir were associated with larger pe
40 h low CD4+ nadir and prior use of stavudine, didanosine, and indinavir.
41 version with the combination of hydroxyurea, didanosine, and indinavir.
42  1 associated with resistance to zidovudine, didanosine, and lamivudine by genotyping by an oligonucl
43 s selected during treatment with zidovudine, didanosine, and nevirapine differed among individuals an
44 fection, combined treatment with zidovudine, didanosine, and nevirapine is well tolerated and has sus
45                                  Zidovudine, didanosine, and nevirapine were administered in combinat
46 ricitabine, abacavir, zidovudine, stavudine, didanosine, and tenofovir and a specific GSS (sGSS) defi
47                  Drugs such as stavudine and didanosine are associated with serious metabolic complic
48 eath were 0.64 (P=0.005) for zidovudine plus didanosine, as compared with zidovudine alone, 0.77 (P=0
49               CD4 cell counts increased with didanosine but declined following the addition of IFN-al
50  cell responses were seen in this zidovudine-didanosine combination pilot study relative to codon 215
51 erval, 1.91-6.20]) or who received stavudine-didanosine combination therapy (odds ratio, 2.23 [95% co
52  study, patients assigned to zidovudine plus didanosine combination therapy experienced a significant
53 2 weeks, followed by 12 weeks of hydroxyurea/didanosine combination therapy for all patients.
54 ficacy for 38 patients receiving hydroxyurea/didanosine combination therapy with findings in 42 perso
55                              The hydroxyurea/didanosine combination was well tolerated.
56 agnitude in the sequence zalcitabine (ddC) > didanosine (ddI metabolized to ddA) > stavudine (d4T) >>
57  zidovudine (AZT) plus zalcitabine (ddC) and didanosine (ddI) develop AZT resistance mediated by muta
58 n from a larger efficacy trial of 2 doses of didanosine (ddI) monotherapy (Pediatric AIDS Clinical Tr
59 als Group 152 study, which demonstrated that didanosine (ddI) or zidovudine + ddI treatments were sup
60                                              Didanosine (ddI) pharmacokinetics in antepartum and post
61 nscriptase (RT) develops as a consequence of didanosine (ddI) therapy and is associated with a decrea
62  randomized either to add stavudine (d4T) or didanosine (ddI) to their current regimen or to switch t
63          In a trial (ACTG 241) of zidovudine/didanosine (ddI) versus zidovudine/ddI/nevirapine in nuc
64  1 (HIV-1) strains that confer resistance to didanosine (ddI) was analyzed in 2 groups of patients re
65    IC(50) values for Zdv, zalcitabine (ddC), didanosine (ddI), 3TC, and stavudine (d4T) were determin
66 The NRTIs zidovudine (AZT), stavudine (d4T), didanosine (ddI), and lamivudine (3TC), and the nucleoti
67 avir, zidovudine (AZT), abacavir, stavudine, didanosine (ddI), and lamivudine] individually or in com
68    Previous treatment with zidovudine (Zdv), didanosine (ddI), or zalcitabine (ddC) was acceptable.
69 airs: zidovudine (ZDV)/lamivudine (3TC), ZDV/didanosine (ddI), stavudine (d4T)/3TC, d4T/ddI, and ddI/
70  retinal pigment epithelial (RPE) cells with didanosine (ddI), which is associated with retinopathy i
71 unodeficiency virus type 1 who switched to a didanosine (ddI)-containing triple- or quadruple-drug re
72 ombination therapy with zidovudine (AZT) and didanosine (ddI).
73  [stavudine (D4T)] and 2'-3'-dideoxyinosine [didanosine (ddI)] likewise stimulated template-switch mu
74 udine [AZT (3'-azido-3'-deoxythymidine)] and didanosine [ddI (2',3'-dideoxyinosine)], in cultured hum
75 ral drugs zidovudine, indinavir sulfate, and didanosine, demonstrating that this model can also be us
76 ne-zidovudine (EFV+3TC-ZDV), atazanavir plus didanosine-EC plus emtricitabine (ATV+DDI+FTC), or efavi
77  n = 289), B (atazanavir, emtricitabine, and didanosine-EC, n = 293), and C (emtricitabine-tenofovir-
78                                 In addition, didanosine exposure was associated with increased corona
79      Among PWH without thymidine analogue or didanosine exposure, time since initiating combination a
80 ogenomics in NCPH in HIV patients with prior didanosine exposure.
81                                              Didanosine failed to reduce the suppressive effects of H
82 r 7 days, (B) zidovudine plus enteric-coated didanosine for 30 days, or (C) regimen 1 for 30 days.
83 experienced subjects received zidovudine and didanosine for 30 weeks followed by 30 weeks of didanosi
84 with zidovudine alone or in combination with didanosine from 22 patients (8 zidovudine-naive and 14 z
85 .20); a higher percentage of the hydroxyurea/didanosine group below the assay's detection limit (500
86  cells for the hydroxyurea/didanosine versus didanosine group of 0 versus 43 cells/mm3 (P=.045), alth
87 s load between hydroxyurea/didanosine versus didanosine groups of -0.93 versus -0.74 log10 copies/mL
88 ination regimen (nevirapine, zidovudine, and didanosine) had an 18% higher mean absolute CD4 cell cou
89          Adding nevirapine to zidovudine and didanosine improved the long-term immunologic and virolo
90 treatment consisted of the nucleoside analog didanosine in the first 43 patients enrolled before Dece
91                                 Abacavir and didanosine increased rolling, adhesion and emigration in
92 viral infection with the nucleoside analogue didanosine is known to cause portal hypertension in a su
93 pies/mL received a once-daily SIT regimen of didanosine, lamivudine, and efavirenz.
94 lity testing of five isolates to zidovudine, didanosine, lamivudine, and nevirapine demonstrated susc
95 tibility of 16 HIV-1 isolates to zidovudine, didanosine, lamivudine, and nevirapine in MT-2 cells.
96  efficacy similar to that of zidovudine plus didanosine (median follow-up, 32 months) (relative risk
97 on therapy with findings in 42 persons given didanosine monotherapy for 12 weeks, followed by 12 week
98  benefits were maintained in this group with didanosine monotherapy.
99 anosine for 30 weeks followed by 30 weeks of didanosine monotherapy.
100            Other agents included zidovudine, didanosine, nevirapine, and saquinavir.
101 nges in susceptibility to ABC, 3TC, TDF, and didanosine on titration of K65R and/or M184V with wild-t
102 teers with >200 x 10(6) CD4 cells/L received didanosine (one 100-, 250-, or 375-mg sachet twice daily
103                                              Didanosine (one 375-mg sachet twice daily) was substitut
104  been identified, such as co-prescription of didanosine or boosted protease inhibitor, preexisting CK
105 me of the antiretroviral drugs (zalcitabine, didanosine or stavudine).
106  therapy consisted of zidovudine plus either didanosine or stavudine.
107 mbination therapy with zidovudine and either didanosine or zalcitabine is not superior to zidovudine
108 ther changing to combination therapy (adding didanosine or zalcitabine) or sequential monotherapy (ch
109 bine) or sequential monotherapy (changing to didanosine or zalcitabine) significantly improves surviv
110 ine alone or zidovudine combined with either didanosine or zalcitabine.
111 and randomly assigned to receive zidovudine, didanosine, or zidovudine plus didanosine.
112 ine alone, didanosine alone, zidovudine plus didanosine, or zidovudine plus zalcitabine.
113 regimens: (A) zidovudine plus enteric-coated didanosine plus lopinavir and ritonavir for 7 days, (B)
114  20 patients evaluable for codon 74 (site of didanosine resistance) had virus that remained wild type
115                                              Didanosine-resistance mutations arose rarely.
116                 Therapy with zidovudine plus didanosine resulted in more gastrointestinal adverse eff
117                  We previously showed that a didanosine-selected mutation in pNL4-3 background confer
118 rd ratio for a first regimen failure, 0.55); didanosine, stavudine, and efavirenz (hazard ratio, 0.63
119  (hazard ratio for regimen failure, 1.24) or didanosine, stavudine, and efavirenz (hazard ratio, 1.01
120 eived the three-drug regimens beginning with didanosine, stavudine, and nelfinavir (hazard ratio for
121 lure than the three-drug regimens containing didanosine, stavudine, and nelfinavir (hazard ratio for
122 at received the four-drug regimen containing didanosine, stavudine, nelfinavir, and efavirenz and the
123 -nevirapine, stavudine-zidovudine, stavudine-didanosine, stavudine-saquinavir, stavudine-nevirapine,
124  randomized ART-naive individuals to receive didanosine-stavudine or zidovudine-lamivudine, combined
125 RMs to drugs not received, such as abacavir, didanosine, tenofovir, etravirine, and rilpivirine.
126    However, in the presence of zidovudine or didanosine, the comparative order for replication was HI
127             In the presence of zidovudine or didanosine, the order was HIV-162/75/77/116/151 > HIV-17
128  HIV-1-infected patients in combination with didanosine; therefore, we investigated the impact of HU
129  administration of a dideoxynucleoside drug, didanosine, to transgenic mice expressing the HIV coat p
130  why NCPH only develops in a small subset of didanosine-treated patients.
131 y found that thrombocytopenia, splenomegaly, didanosine use, elevated aminotransferases, and an eleva
132 dian change in CD4 cells for the hydroxyurea/didanosine versus didanosine group of 0 versus 43 cells/
133 n decrease in virus load between hydroxyurea/didanosine versus didanosine groups of -0.93 versus -0.7
134 sponsible for activation of AIDS drug ddIno (didanosine, Videx) can also, albeit less efficiently, ac
135                                Zidovudine or didanosine was added to cultures in an attempt to revers
136 dine therapy, treatment with zidovudine plus didanosine was associated with a relative risk of diseas
137 h either didanosine alone or zidovudine plus didanosine was more effective than treatment with zidovu
138  levels; and plasma levels of zidovudine and didanosine were measured in patients enrolled at half th
139 se-transcriptase inhibitors, zidovudine, and didanosine were not permitted.
140 V-related factors, apart from treatment with didanosine, were associated with CD4 decline.
141                                  Exposure to didanosine, which is also a purine analogue, predisposes
142 of the patients were receiving tenofovir and didanosine, which may have contributed to this decrease.
143 ults support the association of abacavir and didanosine with CV diseases.
144 sive therapy with combination zidovudine and didanosine with or without nevirapine were identified in
145 zidovudine and zalcitabine or zidovudine and didanosine would delay the emergence of zidovudine-resis
146 nt, whereas susceptibility to group 2 drugs (didanosine, zalcitabine, abacavir, and lamivudine) decre
147 lower-level resistance (3-fold to 5-fold) to didanosine, zalcitabine, and stavudine.
148 ilities of PERV RT to lamivudine, stavudine, didanosine, zalcitabine, and zidovudine were reduced >20
149               Treatment with zidovudine plus didanosine, zidovudine plus zalcitabine, or didanosine a
150 apy duration, smoking, statin use, stavudine/didanosine/zidovudine exposure, time-updated body mass i

 
Page Top